Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bluebird Sickle Cell Gene Therapy Hangs In Balance

Company Probes Causes Of Blood Cancers

Executive Summary

The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.” 

You may also be interested in...



GBT Bucks Gene Therapy Trend With Sanofi Sickle Cell Deal

Building on Oxbryta, which is already approved in the US for the rare blood disorder, Global Blood Therapeutics has licensed two sickle cell disease programs from Sanofi.

Bluebird Lenti-D Data Give Gene Therapy Business Another Boost

The news comes less than a week after data partially exonerated its other gene therapy in a cancer scare announced in February.

Bluebird Bio Gets Relief, But Gene Therapy Hurdles Remain

The jury is still out on the case of MDS and some remaining questions regarding the AML case may still hinder commercial uptake.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel